IJMSC: Variables Associated with Self-reported Language Impairment in Multiple Sclerosis: A Regression Analysis

Release Date: April1, 2021 Valid for Credit Through: April 1, 2022 Variables Associated with Self-reported Language Impairment in Multiple Sclerosis: A Regression Analysis Sarah El-Wahsh, BAppSc (Sp Path) (Hons 1); Rob Heard, PhD; Hans Bogaardt, PhD; Fiona Kumfor, PhD; Kirrie J. Ballard, PhD Target Audience: The target audience for this activity is physicians, physician assistants, …

Therapeutic Advances in the Management of Relapsing Forms of Multiple Sclerosis

Release Date: 3/12/2021 Expiration Date: 3/11/2022 Provider Statement This continuing education activity is provided by   Support Statement This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. Target Audience The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management …

AIMS Peer-to-Peer Podcasts

New Podcasts Available for Clinicians to Earn CE Credit! Earn up to 0.75 CE Credits Sit back and listen to three exciting and insightful podcasts from top MS experts. Featuring discussions on the clinical course of MS (Drs. Fred Lublin and Robert Shin), MS assessment (Drs. Patricia Coyle and Robert Shin), and shared decision-making strategies …

Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management

Released: January 11, 2021 Expires: January 11, 2022 Program Description This activity provides an overview of the role of the innate and adaptive immune systems in the development and progression of multiple sclerosis (MS), while exploring the therapeutic implications of immune dysfunction. MS immunotherapies are reviewed, with a focus on their mechanisms of action and …

Initiating or Switching Therapy in Multiple Sclerosis: New Evidence and Expert Insights

*US and Canadian HCPs* Release Date: November 30, 2020 Expiration Date: November 30, 2021 Intended Audience: Physicians and their teams providing care for patients with MS (PAs, NPs, nurses, pharmacists) Accompanying this activity are resources to provide evidence-based guidance on necessary laboratory evaluations needed before initiating or switching DMTs, as well as a guide for …

IJMSC: Identifying Barriers to and Facilitators of Health Service Access Encountered by Individuals with Multiple Sclerosis

Release Date: February 1, 2021 Valid for Credit Through: February 1, 2022 Identifying Barriers to and Facilitators of Health Service Access Encountered by Individuals with Multiple Sclerosis Chantel D. Mayo, MSc*; Negar Farzam-kia, BSc*; Setareh Ghahari, PhD, OT Reg (Ont) Target Audience: The target audience for this activity is physicians, physician assistants, nursing professionals, mental …

Examining the Evidence for Early Initiation of Disease-Modifying Therapy

RELEASE DATE: December 21, 2020 VALID FOR CREDIT THROUGH: December 21, 2021 Provided by The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses and Spire Learning. This activity is supported by an educational grant from Genentech, a member of the Roche Group. PRIMARY AUDIENCE: This multidisciplinary educational initiative is targeted to …

Exploring the Use of Diagnostic Tools to Improve Early Detection of MS

RELEASE DATE: December 21, 2020 VALID FOR CREDIT THROUGH: December 21, 2021 Provided by The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses and Spire Learning. This activity is supported by an educational grant from Genentech, a member of the Roche Group. PRIMARY AUDIENCE: This multidisciplinary educational initiative is targeted to …

Clinical Insights on When and How to Switch DMT in Patients With a Suboptimal Treatment Response

RELEASE DATE: December 21, 2020 VALID FOR CREDIT THROUGH: December 21, 2021 Provided by The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses and Spire Learning. This activity is supported by an educational grant from Genentech, a member of the Roche Group. PRIMARY AUDIENCE: This multidisciplinary educational initiative is targeted to …

What Is Disease Modifying Therapy? Evidence-Based Disease Modification in Multiple Sclerosis

RELEASE DATE: December 30, 2020 VALID FOR CREDIT THROUGH: December 30, 2021 Provided by The Consortium of Multiple Sclerosis Centers and Catamount Medical Education. This activity is supported by an independent education grant from Sanofi Genzyme. Credit Available Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™ Nurses — maximum of 1.0 contact hours of continuing nursing …